Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for metastatic renal cell carcinoma (mRCC): outcomes in the combined IMDC intermediate/poor risk and sarcomatoid subgroups of the phase 3 KEYNOTE-426 study
Rini, BI Plimack, ER Stus, V Gafanov, R Hawkins, Robert E Nosov, D Pouliot, F Soulieres, D Melichar, B Vynnychenko, I
Rini, BI
Plimack, ER
Stus, V
Gafanov, R
Hawkins, Robert E
Nosov, D
Pouliot, F
Soulieres, D
Melichar, B
Vynnychenko, I
Citations
Altmetric:
Abstract
Description
Date
2019
Publisher
Collections
Keywords
Type
Meetings and Proceedings
Citation
Rini BI, Plimack ER, Stus V, Gafanov R, Hawkins R, Nosov D, et al. Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for metastatic renal cell carcinoma (mRCC): outcomes in the combined IMDC intermediate/poor risk and sarcomatoid subgroups of the phase 3 KEYNOTE-426 study. J Clin Oncol. 2019;37(15_suppl):4500-.